Could less be more? study tests cutting biologic doses for Crohn's and colitis
NCT ID NCT07303686
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether people with Crohn's disease or ulcerative colitis who are in deep remission can safely reduce their dose of the biologic drug ustekinumab. Participants will either switch from injections every 4 weeks to every 8 weeks, or from every 8 weeks to every 12 weeks. Researchers will monitor blood levels, inflammation markers, and gut health to see if remission holds. The goal is to find out if lower doses can still keep the disease under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ustekinumab
What this could lead to
If successful, this could show that some patients with Crohn's disease or ulcerative colitis can safely take less medication while staying well, reducing treatment burden and side effects.
What could go wrong
This is a small pilot study, so results may not apply to everyone. Reducing the dose could cause the disease to flare up again, and the study does not yet prove long-term safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MUHC - Montreal General Hospital
RECRUITINGMontreal, Quebec, H3G1A4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••